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Abbreviations 
 
AF - Atrial Fibrillation 
ARVD - Arrhythmogenic Right Ventricular Dysplasia 
BNP - B-type natriuretic peptide 
CAC – Coronary Artery Calcification 
CHD - Coronary Heart Disease 
CT – Computed Tomography 
CV – Cardiovascular 
CRF – Cardiorespiratory Fitness 
ECG – Electrocardiogram  
HCM - Hypertrophic Cardiomyopathy 
MI – Myocardial Infarction 
PA – Physical Activity 
RA / LA – Right and Left Atria 
RV – Right Ventricle  
SCD – Sudden Cardiac Death 
US – United States 
VT - Ventricular Tachycardia  
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Abstract 
The  question  is  not  whether  exercise  is  or  isn’t  one  of  the  very  best  strategies  for  
improving quality of life, cardiovascular (CV) health and longevity—it is. And there is no 
debate as to whether or not strenuous high-intensity endurance training produces an 
amazingly efficient, compliant, and powerful pump—it does. The essence of the 
controversy centers on what exactly is the ideal pattern of long-term physical activity 
(PA) for conferring robust and enduring CV health, while also optimizing life expectancy. 
With  that  goal  in  mind,  this  review  will  focus  on  the  question:  “Is  more  always  better  
when  it  comes  to  exercise?”  And  if  a  dose-response curve exists for the therapeutic 
effects of PA, where is the upper threshold at which point further training begins to 
detract from the health and longevity benefits noted with moderate exercise? The 
emerging picture from the cumulative data on this hotly debated topic is that moderate 
exercise appears to be the sweet spot for bestowing lasting CV health and longevity. 
However, the specific definition of moderate in this context is not clear yet.  
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Part 1 
Exercising for Peak Fitness versus Health and Longevity 
 
Physical exercise when performed regularly is one of the best strategies for enhancing 
quality of life, improving CV health and lengthening life expectancy.1-3  However, 
emerging scientific evidence indicates that exercise practices that are ideal for 
conferring CV health and longevity may differ from the high-intensity, high-volume 
endurance training programs that are effective for developing peak cardiac performance 
and elite-level cardiorespiratory fitness (CRF).4 Progressively enhancing CRF levels 
from low to moderate to high will proportionately improve CV prognosis and overall life 
expectancy.5  However, the longevity dividends related to incremental increases in CRF 
plateau at about 10 metabolic equivalents (METS), with no further rise in life expectancy 
accruing from higher levels of CRF.5-7 Although a regimen of 30 minutes of moderate or 
vigorous physical activity (PA) on most days of the week will improve health and well-
being, increasing the dose of exercise to daily multi-hour bouts of strenuous exercise 
will not magnify the health benefits. In fact, an evolving body of evidence suggests that 
excessive doses of exercise may trigger acute transient myocardial dysfunction with 
subsequent pathological rises in levels of cardiac troponin and B-type natriuretic peptide 
(BNP).8-9  
 
 
Exercise and Survival: More is not Always Better 
 
 
Epidemiological studies of healthy populations have found reverse-J-curve or U-curve 
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relationships for exercise dose and long-term CV health and life expectancy.10-12 
Moderate exercise, as compared to a sedentary lifestyle, markedly lowers the risk for 
CV events and all-cause mortality.10-12 However, progressively excessive regimens of 
chronic endurance exercise partially erase the longevity benefits associated with light 
and moderate exercise regimens.  
 
The Aerobics Center Longitudinal Study  
 
An important recent study by Lee, Lavie and colleagues focused on the mortality effects 
of running among a cohort of 55,000 adults ages 18 to 100 years followed for a mean of 
15 years.13 Using comprehensive analyses that controlled for potential confounding 
factors, they found that runners (as compared to non-runners) had 30% and 45% lower 
risks of all-cause and CV mortality, respectively, with a mean improvement in life 
expectancy of 3-years.  However, the maximal CV longevity benefits were noted with 
moderate doses of running: specifically 6 to 12 miles run per week, with running 
durations of about 50 to 120 minutes per week, with a running frequency of about 3 
times per week, and a modest pace of about 6 to 7 miles per hour.  Higher weekly 
doses of running were associated with loss of approximately one-third to one-half of the 
CV mortality benefits noted from the moderate doses of running. (Figure 1A and 1B) 
 
The Copenhagen City Heart Study 
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In this prospective longitudinal study, 1,098 healthy joggers and 3,950 healthy non-
joggers were followed for 12 years.14 The cohort of individuals jogging 1 to 2.4 hours per 
week had a 50% lower mortality rate compared to the sedentary control group. In this 
study, the optimal frequency of jogging was from 2 to 3 times per week, and the optimal 
running speed was either a slow or average pace. When the joggers were divided into 3 
groups—light, moderate, or strenuous—according to running dose (as calibrated by 
pace, jogging duration, and frequency of runs), a U-shaped association between all-
cause mortality and running dose was apparent. Light and moderate joggers had lower 
mortality rates than sedentary people; in contrast, strenuous runners had a mortality 
rate statistically similar to the sedentary group. (Figure 2) 
 
 
Exercise Dose-Response Curve among Coronary Disease Patients 
 
A study  utilizing  the  National  Walkers’  and  Runners’  Health  Studies  database  followed 
2,377 survivors of myocardial infarction (MI) with the goal of assessing the dose-
response relationship between exercise and long-term CV mortality.1 Compared to a 
sedentary lifestyle, a regular regimen of running or walking was associated with 
progressive dose-dependent reductions in CV mortality.  Maximal benefits, including up 
to 65% reductions in CV mortality, were seen among cohorts running 20 to 30 miles (32 
to 48 km) per week, or walking 35 to 45 miles (56 to 73 km) per week. However, for 
cohorts who were exercising above these thresholds, much of the CV mortality benefit 
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was lost in a U-curve pattern. (Figure 3) Of interest, this data set from the National 
Walkers’  and  Runners’  Health  Studies  confirmed  prior  reports  indicating  that  the  CV  
longevity benefits of walking and running were equal as long as the number of calories 
burned during exercise—energy expenditures—were equivalent.1 For example, the 
duration of exercise required to burn 300 calories will be about twice as long for walking 
(about 50 to 60 minutes) compared to jogging (about 25 to 30 minutes).  
 
Another very recent cohort study reported a reverse-J-curve pattern for exercise among 
1038 individuals with stable coronary heart disease (CHD).2 This study also found that 
inactive individuals were at the maximum risk for adverse health outcomes, with the 
moderate exercise cohort at the lowest risk. Intermediate in risk was the most physically 
active cohort (those doing strenuous exercise on a daily basis), who displayed a risk of 
CV mortality that was higher than the moderately active cohort, but not as high as the 
sedentary cohort. Over the 10-year follow-up period, that study found that the sedentary 
cohort was at 2-fold increased risk of MI or stroke and 4-fold higher risk of all-cause 
mortality compared with the moderately active group. However, the cohort who 
performed strenuous exercise on a nearly every day basis was also at higher risk—
showing a 2-fold risk of fatal MI or stroke compared to the moderately active cohort.2 
 
 
Exercise and Atrial Fibrillation 
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A growing number of epidemiological and observational studies consistently report 
strong statistically significant associations between chronic high-intensity endurance 
exercise and a higher risk for atrial fibrillation (AF).15-18 The impact of habitual exercise 
on the risk of AF, similar to the risk of early mortality, appears to also be nonlinear. 
Moderately active individuals have lower rates of AF compared to sedentary people; 
however higher rates of AF (in a J-curve pattern) are seen among individuals getting 
excessive chronic doses of vigorous, high-intensity exercise.17-18 
 
A recent population-based cohort study evaluated the link between exercise and the risk 
of AF among 44,410 Swedish males.17 The researchers reported that intense exercise 
of more than 5 hours per week at age 30 years heightened the risk of developing AF 
later in life. In contradistinction, moderate-intensity exercise, such as walking or 
recreational cycling, during middle age decreased the risk of AF.17 In a similar 
prospective observational study of older men and women (mean age 73 years), 
moderate-intensity exercise like walking reduced the risk for AF by about 33%.18 
However, a reverse J-shaped relationship was again apparent for exercise intensity 
showing that extreme exercise increased risk of AF compared to moderate exercise 
(Figure 4). Yet another recent and large cohort study, this one evaluating 52,755 long-
distance cross-country skiers competing in a yearly 90-km race in Sweden, found higher 
rates of arrhythmias including AF among the men and women who had the fastest 
finishing times and the greatest number of completed cross-country skiing races.15 
Fortunately, the risk of AF seems to resolve or substantially diminish with detraining and 
moderation of the excessive exercise dosing, likely due at least in part to normalization 
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of the autonomic tone.19 
 
Marathon Running and CV Health 
 
The number of individuals in the United States (US) running in marathons has increased 
25-fold over the past 4 decades.3 Despite the excellent risk factor profiles and the 
generally superb CRF of long-distance runners, race-related cardiac deaths among 
marathon runners occur regularly, albeit rarely.20 Surprisingly, long-term marathon 
running has in some studies been linked to accelerated, not diminished, coronary 
plaque development. Schwartz et al21 discovered that on coronary angiography, veteran 
endurance male runners (who had run one or more marathons each year for 25 
consecutive years) had significantly greater accumulations of both hard and soft 
coronary plaque compared to control group of sedentary age-matched men. (Figure 5)  
 
Female Marathon Resilience 
 
Schwartz and colleagues studied both genders among the Twin Cities Marathon 
participants in recent decades, and found that among 25 female veteran marathoners 
(unlike their male marathoner counterparts) did not show an increase in the coronary 
plaque burden compared to a control group of sedentary women (Schwartz RS and 
O'Keefe JH, unpublished observations  in the female marathoners).21 Intriguingly, the 
per capita incidence of race deaths among marathoners is approximately 5-fold higher 
for men than women.20 A recent study of over 90,000 marathon finishers found that 
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women tend to pace themselves during a race better than men do.20 Women marathon 
runners are much more likely than men to maintain a steady, less pressured, pace 
throughout the race, and thus perhaps are also less likely to break down physically 
during the event.22  
 
Cardiac Overuse Injury 
 
We  have  suggested  the  term  “cardiac  overuse  injury”  to  describe  the  constellation  of  
heart abnormalities that can arise among otherwise healthy endurance athletes. Many 
veteran aerobic athletes have personal experience with orthopedic overuse injuries 
such as plantar fasciitis, Achilles tendonitis, shin splints, tennis elbow and patellar 
chondromalacia. Both categories of overuse injury—orthopedic and cardiac—develop 
as a consequence of a high-volume and/or high-intensity training regimen.3, 10 However, 
orthopedic overuse injuries tend to be more self-limiting, whereas cardiac overuse 
injury, if sustained over prolonged periods of training and racing, can predispose to 
ominous outcomes, including dangerous cardiac arrhythmias, premature aging of the 
heart, accelerated coronary plaque formation, myocardial fibrosis, plaque rupture with 
acute coronary thrombosis, and, rarely, even sudden cardiac death (SCD).11 
 
As in orthopedic overuse injuries, repetitive micro-trauma causes cardiac overuse 
injuries, which often present with subtle symptoms and progress gradually. Overuse 
injuries of all types are challenging to diagnose and treat, and often become chronic 
AC
CE
PT
ED
 M
AN
US
CR
IPT
ACCEPTED MANUSCRIPT
11 
 
ailments in part because the afflicted athletes are often reluctant to de-escalate their 
training regimens.  
 
How Do Cardiac Overuse Injuries Occur?  
 
The heart has a tremendous capacity to adapt to chronic exercise demands. Indeed, 
many positive CV adaptations occur with long-term PA; these are essential for improved 
fitness and tend to promote good CV health. With exercise the heart grows stronger and 
more functional through adaptive remodeling—which involves a balance between the 
break down and rebuilding of myocardial tissue.  
 
Higher doses of aerobic exercise are associated with incrementally better CRF, as well 
as dose-dependent improvement of many CV risk factors including abdominal obesity, 
glucose metabolism, and high-density lipoprotein cholesterol. Additionally, masters level 
endurance athletes show youthful levels of left ventricular compliance.23   
 
An “arms  race”  among endurance athletes has led to progressively more unreasonable 
training regimens and races in recent years. For example, Race Across America 
(RAAM) is a non- stop transcontinental bicycle race; Self-Transcendence is a 3100-mile 
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run, and Trans Europe is a footrace of about 3,000 miles.24 (Figure 6) The director of 
Boundless, a television show that follows two athletes as they compete in some of the 
world's toughest endurance challenges, was quoted "I want you guys to enter races 
where you almost die, but still make it to the finish line."25  
 
Some individuals may be more prone to cardiac overuse injuries due to genetic 
predisposition, existing cardiac disease or CV risk factors, lifestyle issues such as 
excess alcohol intake, psychosocial stress, inadequate rest and recovery, suboptimal 
diet, or use of performance enhancing agents like anabolic steroids, or amphetamines. 
Importantly, aging predisposes to cardiac overuse injury just as it does for orthopedic 
overuse injuries. Thus, moderating exercise to avoid chronic ultra-endurance efforts 
may be especially relevant for individuals beyond 45 or 50 years of age. Competitive 
athletes often train and race even when they are fighting off illnesses, such as influenza 
and other potentially cardio-toxic viral infections, which also might predispose to CV 
damage. All of these issues remain hypothetical, and will require future research for 
clarification.  
 
Adverse CV Remodeling 
 
An animal model of chronic high-intensity endurance exercise training forced rats (using 
tail shocks if their pace slowed) to run vigorously and continuously for 60 minutes daily 
during a 4-month span.8, 26 The running rats developed ventricular hypertrophy, and 
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fibrosis (collagen deposition) in the right and left atria (RA and LA), the right ventricle 
(RV) and interventricular septum. Ventricular tachycardia (VT) was inducible in 42% of 
the running rats compared to 6% of the sedentary rats (P=.05). Subsequently, after the 
forced daily running regimen was terminated, the fibrotic changes in the heart partially 
regressed to normal by 8 weeks. This animal study found that daily strenuous 
uninterrupted running reproduced the proarrhythmic adverse cardiac remodeling 
observed in some ultra endurance athletes.8, 26 
 
Resting cardiac output is about 5 L/min, but is capable of increasing during vigorous 
exercise 5-fold to about 25 L/min (often much higher yet in elite endurance athletes),18 
causing acute dilation of the LA, RA, and RV. This recurrent stretching of the myocardial 
fibers under conditions of high oxidant stress and sustained elevations in 
catecholamines may eventually induce adverse structural changes also, especially in 
the low pressure, pliable cardiac chambers. Multiple studies show dilatation and patchy 
scarring of the RV, ventricular septum, and atria in some veteran endurance athletes.15-
16, 27-28  
 
La Gerche et al29 evaluated a group of 40 highly trained athletes competing in 
endurance events, including marathons (mean time to completion, 3 hours), half-
ironman triathlons (5.5 hours), full-ironman triathlons (11 hours), and alpine bicycle 
races (8 hours). These demanding endurance exercise efforts triggered rises in 
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biomarkers of myocardial injury (troponin and BNP), which were proportional to 
immediate post-race transient reductions in RV systolic function by echocardiography.29  
 
Multiple studies have reported that endurance athletes who have symptoms of 
arrhythmias are much more likely to show RV dilation and decreased RV ejection 
fraction.30-31 Notably, during extreme and sustained high-level exercise, some 
individuals show marked elevations in pulmonary artery pressures of up to 80 mm Hg.32 
A few small studies have reported myocardial scarring (as detected by late gadolinium 
enhancement on magnetic resonance imaging/MRI) in the ventricular septum, with an 
incidence ranging from 12 to 50% among middle-aged veteran ultra-endurance 
athletes.29, 33-34  
 
Additionally, ventricular ectopy, including VT,35 can occur in endurance athletes, even 
among highly fit individuals.20, 30 The ventricular ectopy in endurance athletes typically 
arises from the RV or the interventricular septum.30-31, 36-38 Patchy myocardial fibrosis 
(scar tissue) resulting from cardiac overuse injury could provide the substrate for 
ventricular irritability and reentry arrhythmias.30, 39 However, as La Gerche and 
colleagues40 have recently reviewed, competitive athletes may have more arrhythmias, 
but overall may still have more favorable longevity due to other beneficial effects of 
training.  
 
Risk Stratification for Endurance Athletes 
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To date, no screening strategy has been found to be effective for detecting CV 
pathologic changes due to excessive endurance exercise. In symptomatic individuals 
who are complaining of arrhythmias, or other CV symptoms, using echocardiography or 
MRI to identify adverse structural remodeling and substrate for arrhythmias is 
theoretically logical.37  Computed tomography (CT) to screen for and score coronary 
artery calcification (CAC) may be useful and is much less expensive than MRI and 
echocardiography. CT-CAC scoring may be especially useful for endurance athletes 
over age 45 or 50 years. Exercise testing is generally not a sensitive strategy for 
screening ultra endurance athletes.  Cost-effectiveness and/or clinical accuracy for 
detecting cardiac overuse injury are not available for any testing modality.   
 
Exercise Dosing for Maximizing CV Health and Longevity 
 
Physical inactivity is a much more prevalent public health problem than is excessive 
exercise. A recent survey of 500,000 American adults reported that about 50% of 
people do not meet the suggested minimum exercise dose of 150 minutes per week of 
moderate-intensity aerobic PA.41 On the other hand, extrapolation of the Williams and 
Thompson1 data-set indicate that a small minority of runners and walkers in the US may 
be overdosing their PA, potentially increasing the risk-to-benefit ratio of their exercise 
program. (Figure 7) People on the margins of either end of the exercise spectrum 
(sedentary individuals and over-exercisers) would likely improve their long-term CV 
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health and longevity by altering their daily PA pattern so to be in the safe moderate 
range. 
 
Exercise is unequaled for its power to enhance quality of life and CV health, and in this 
regard can be thought of as a therapeutic agent. Thus, when prescribing exercise we 
should think of potential indications and contraindications, and customize the 
prescription to the individual. As with any potent therapy, ascertaining the safe and 
effective dose range is vitally important—an inadequately low dose may not confer full 
benefits, while an overdose may cause hazardous adverse effects that outweigh its 
benefits. Thankfully, the exercise dose-response range that is safe and effective for 
optimizing CV health and longevity is broad. Desperately needed public health efforts to 
reduce physical inactivity and prolonged periods of sitting are underway and gaining 
momentum. Yet, attention should also be focused on delivering the message that even 
light and moderate doses of exercise can bestow powerful health benefits, and it is very 
possible that excessively strenuous chronic exercise may erode some of the health 
dividends of less extreme PA.42 
 
The emerging data suggest that is may be sensible to limit chronic vigorous exercise to 
no more than about 60 minutes per day.1-3, 13, 17 More support for this recommendation 
comes from a recent trial of 60 men with stable CHD who were randomized to 
strenuous aerobic exercise sessions lasting either 30 or 60 minutes.27 The 30-minute 
exercise bouts enhanced arterial elasticity yet generated only minimal oxidative stress. 
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In contrast, the 60-minute sessions transiently stiffened blood vessels and markedly 
increased the oxidant stress, especially among men over age 50 years.27 
 
A cumulative weekly dose of strenuous exercise of not more than about 5 hours has 
been suggested in several studies to be near the safe upper limit for conferring optimal 
long-term CV health and overall longevity.1-3, 10-13, 17, 27 It also appears to be beneficial to 
avoid performing high-intensity exercise on an everyday basis, and to instead take 1 or 
2 days a week off to allow the body and heart to rest and recover.1-3, 10-13, 17 
 
Summary of Part 1 
 
If  one’s  goal  is  to  decrease  risk  of  CV  death  and  improve  life  expectancy,  going  for  a  
short, leisurely jog a few times per week is adequate. High-volume, high-intensity 
training is not just unnecessary—very high doses of chronic PA may diminish some of 
the remarkable CV benefits conferred by moderate exercise. In fact, based upon the 
best data available, a running dose that appears to be highly favorable for reducing CV 
mortality (though far below the dose for maximizing CRF) is: jogging about 3 days per 
week, with a cumulative distance of 6 miles per week, at a pace of 6 or 7 miles per hour 
(corresponding to 8.5 to 10 minutes per mile). Many people would perceive this to be a 
goal that is reasonable, achievable and sustainable.    
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Part 2: 
 
Screening of School-age Athletes 
 
 
 
SCD in young competitive athletes or older athletes is a tragic event.  In most cases of 
this type, SCD is secondary to malignant ventricular arrhythmias that is caused by 
underlying structural CV disease.1-4 Cardiomyopathies have been consistently 
implicated as the leading cause of SCD in young competitive athletes, especially with 
hypertrophic cardiomyopathy (HCM) accounting for over a third of the cases in the US, 
whereas arrhythmogenic right ventricular dysplasia (ARVD) causes almost a quarter of 
the fatal cases in Italy.43 
 
A major issue is whether there should be a preparticipation screening for athletes and 
what this should entail, with quite different recommendations currently coming from 
different countries, such as the US and Italy.43-47 Currently, medical evaluations of 
competitive athletes prior to competition offers the potential to identify asymptomatic 
athletes with potentially life-threatening CV disorders and to prevent SCD through 
disqualification from highly competitive sports.  Certainly, SCD in young competitive 
athletes are highly visible and emotional events with considerable impact on physicians 
and the lay communities.  However, the magnitude of this topic from a public health 
perspective has been hotly debated. 
 
Analysis of Recent US Deaths  
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Recently, Maron and colleagues44 reviewed SCD in young competitive athletes 
(n=1,866) from 1980-2006.  In this large national registry, SCD was predominantly due 
to CV disease (56%); the most common being HCM (36%) and coronary artery 
anomalies (17%).  In this cohort, 29% of the events occurred in African Americans, 54% 
in high school students and 82% with physical exertion.  The absolute number of events 
was relatively low (<100 per year on average), although somewhat higher than 
previously estimated.  The authors concluded that their data were quite relevant to the 
current debate about preparticipation screening with electrocardiograms (ECGs).   
 
 
Benefits of Preparticipation Screening in Italy 
 
"He who saves a single life saves the whole world" 
Talmud Sanhedrin 4:548 
 
Italian law mandates that every participant engaged in competitive sports activity must 
undergo a clinical evaluation and obtain eligibility.43-49  In fact, a nationwide systematic 
screening program, which was largely based on a preparticipation 12-lead ECG, was 
launched in 1982.  Several years ago, Corrado and colleagues43 reported that following 
this intervention program, CV deaths fell by 44% in the early screening program 
(P=0.001) and by 79% in the late screening program (P=0.001).  During the study 
period, 2% of athletes were disqualified for CV diseases.  The major fall in SCD in this 
analysis was secondary to a low incidence of SCD from cardiomyopathies. 
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Comparison of US and Italian Experience with SCD in Athletes 
 
Maron and colleagues45 recently analyzed the SCD rate among competitive athletes in 
Minnesota compared with that from Italy.  They demonstrated that CV death in Venito, 
Italy exceeded that in Minnesota for the 11 year period (1993-2014).  They concluded 
that despite quite different preparticipation screening (history and physical exam in the 
US without any formal diagnostic testing versus ECG testing plus examination in Italy), 
the SCD rate did not differ considerably, suggesting that their data did not support a 
lower mortality rate associated with preparticipation screening programs involving 
routine ECG and examinations by training personnel. 
 
Experience in Israel 
 
Several years ago, Steinvil and colleagues46 reported the Israel experience before and 
after an ECG screening program for athletes.  They reported except for a spike in the 
Israel SCD event rate in 1995/96, the rate of SCD in Israel was similar before and after 
the Israeli Sports Law was implemented in 1997/98 and was similar to that noted in Italy 
and Minnesota (Figure 8).  They concluded that mandatory ECG screening of athletes 
had no apparent effect on the risk of SCD in athletes.   
 
 
Major Recommendations from the US and Europe  
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The various recommendations from the US and Europe have recently been reviewed, 
including the Bethesda Conference #36 and the European Society of Cardiology 
Consensus Recommendations with the differences in the recommendations 
summarized in Table 1.47, 50  Clearly, the European Society of Cardiology Guidelines 
are considerably more restrictive than the US (Bethesda Conference #36) Guidelines.  
Italy has particularly restricted guidelines, including screening all athletes yearly with 
Sports Medicine history, physical examination and ECG.  On the other hand, in the US, 
athletes  obtained  their  own  physician’s  clearance,  which  is  generally  not  very  intensive,  
but often includes a brief history and physical examination. 
 
 
It seems apparent at some point in time to consider assembling updated 
recommendations from experts from around the world to determine sports eligibility and 
criteria for disqualification that includes both the US and European perspectives that is 
applicable to the Global Sports Medicine Community.  Certainly, at present, the cost-
effectiveness of more formal testing, including ECG and, even more so, for 
echocardiography, is questionable.47, 50  Despite this, there may be some subgroups 
(e.g., possibly African American basketball players), who may be at higher risk and 
could benefit from more intensive testing, although this hypothesis is currently 
unproven. 
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At present, it is clear that HCM cannot be cleared.  Long Congenital QT Syndrome 
(defined as QTc >0.47 seconds in males and 0.48 seconds in females in US or 0.44 
seconds and 0.46 seconds, respectively in Europe) cannot be cleared.  Brugada 
Syndrome and Catecholamine Polymorphic VT cannot be cleared.  Marfan's cannot be 
cleared  when  the  aortic  root  is  >40  mm,  as  well  as  those  with  Marfan’s  and  either  
moderate-severe mitral regurgitation or a family history of aortic dissection or SCD.  In 
Wolff-Parkinson-White Syndrome, clinicians could consider electrophysiologic testing 
and need for radiofrequency ablation for symptoms or for AF.  Severe aortic stenosis 
and severe aortic regurgitation generally cannot be cleared, whereas severe mitral 
regurgitation with preserved left ventricular function in asymptomatic patients generally 
can be cleared.  Nevertheless, further defining these recommendations is clearly 
needed.47, 50 
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Figure Legends: 
Figure 1A and 1B: Cardiovascular Mortality by Running Distance, Frequency, Total 
Amount, and Speed. Participants were classified into 6 groups: nonrunners and 5 
quintiles of each running distance, frequency, total amount, and speed. All hazard ratios 
(HRs) were fully adjusted for baseline risk factors. The bars indicate 95% CI, and HRs 
are shown next to the bars. MET = metabolic equivalent.13 Permission received. 
 
Figure 2: Mortality in light, moderate and strenuous joggers compared to sedentary non-
joggers.14 Permission received. 
 
Figure 3: Risk of death during follow up as a function of exercise-related energy 
expenditure. Increasingly higher doses of exercise, via walking and/or running, 
proportionately reduced the risk for all-cause mortality and CV mortality up to 7.2 
METh/d—equivalent to running 30 miles per week, or briskly walking 46 miles per week. 
Higher weekly exercise efforts beyond this threshold negated the benefits noted with the 
exercise doses from the first four quintiles.1 Permission received.  
 
Figure 4: Risk of new-onset atrial fibrillation (Afib) among 5,446 older adults (> 65 years 
of age) as a function of exercise intensity. Low and moderate intensity exercise reduced 
risk of Afib; however, some of this protection was lost in the high-intensity exercise 
group.4 Permission received.  
 
Figure 5: Male marathoners had significantly more total coronary plaque volume, non-
calcified plaque volume and calcified plaque volume compared to sedentary control 
subjects.4 Permission received.  
 
Figure 6:  During the TransEurope FootRace in 2009 15 runners were followed with 
serial magnetic resonance imaging brain scans before, during and after this 4,487 km 
ultramarathon. The data depicted here showed 6% mean reduction in grey matter. This 
decrease in brain volume returned to baseline by 8 months after the race.24 Permission 
received from Biomed Central, original publisher of Figure 2.  
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Figure 7: About half of the population does not meet the minimum recommended 
amount of physical activity per week. However, a small minority, about 2.5%, may be 
overdoing aerobic exercise.1, 41 Figure made from information in manuscript. 
 
Figure 8 – The Italian study (4) (pink graph) concluded that electrocardiography (ECG) 
screening (started in 1982) significantly reduced the incidence of sudden cardiac death 
by comparing the sudden death in the 2-year pre-screening period (A to B) with the 
post-screening period (B to F). The present study is depicted by the green graph. We 
compared the 12 years before screening (C to E) with the 12 years after the onset of 
mandatory ECG screening (E to G). Had we limited our comparison of the 
postscreening period to the 2-year period preceding the enforcement of screening in 
Israel (D to E vs. E to G, as performed in the Italian study), we would have concluded 
erroneously that screening saved lives of athletes in Israel. The study from Minnesota 
(19) (yellow graph) shows a low mortality rate in a population of athletes not undergoing 
systematic ECG screening.46 Permission received.  
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Table 1.  Summary of Selected Differences Between BC#36 and ESC 
Recommendations for Competitive Athletes with Selected CV Abnormalities. 
 
 
  
Clinical Criteria and Sports Permitted 
 
BC#36 
 
ESC 
Gene carries without phenotype 
(HCM, ARVC, DCM, Ion 
channel diseases*) 
All sports Only recreational sports 
LQTS > 0.47 s in male subjects, 
     > 0.48 s in female subjects 
Low-intensity competitive sports 
> 0.44 s in male subjects, 
     > 0.46 s in female subjects 
Only recreational sports 
Marfan syndrome  If aortic root < 40 mm, no MR, no 
familial SD, then low-moderate 
intensity competitive sports 
permitted 
Only recreational sports 
 
Asymptomatic WPW EPS not mandatory 
 
All competitive sports (restriction 
for sports in dangerous 
environment)† 
EPS mandatory 
 
All competitive sports (restriction 
for sports in dangerous 
environment)† 
Premature ventricular 
complexes 
All competitive sports, when no 
increase in PVCs or symptoms 
occur with exercise 
All competitive sports, when no 
increase in PVCs, couplets, or 
symptoms occur with exercise 
Nonsustained ventricular 
tachycardia  
If no CV disease, all competitive 
sports 
 
If CV disease, only low-intensity 
     competitive sports 
If no CV disease, all competitive 
sports 
 
If CV disease, only recreational 
sports 
 
*Long-QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia; 
†sports  in  dangerous  environments  are  restricted,  given  the  risk  should  impaired  consciousness  occur,  
such as motor sports, rock climbing, and downhill skiing. 
 
ARVC = arrhythmogenic right ventricular cardiomyopathy; BC#36 = Bethesda Conference # 36; CV = 
cardiovascular; DCM = dilated cardiomyopathy; EPS = electrophysiologic study; ESC = European Society 
of Cardiology; HCM = hypertrophic cardiomyopathy; MR = magnetic resonance; PVC = premature 
ventricular complex; SD = sudden death; WPW = Wolff-Parkinson-White syndrome.   
 
Reproduced with permission from Pelliccia et al.46 
 
 
